Endocrine Abstracts

Small cell lung cancer (SCLC) is the most aggressive form of lung cancer as it lacks known targets of therapy. 5-year survival is only 5% and patients quickly develop therapy resistance by yet unknown mechanisms. The lack of advances is also related to the fact that SCLC is not part of the ICGC or TCGA cancer genomics projects, and patient material is hard to obtain. SCLC presents frequent amplifications in genes of the MYC family, which are known regulators of splicing factor...